Medicamen Biotech Ltd vs Mercury Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Medicamen Biotech Ltd is ₹ 267.4 as of 18 May 15:30 . The P/E Ratio of Medicamen Biotech Ltd changed from 53.8 on March 2021 to 86.2 on March 2025 . This represents a CAGR of 9.89% over 5 yearsThe P/E Ratio of Mercury Laboratories Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Medicamen Biotech Ltd changed from ₹ 652.37 crore on March 2021 to ₹ 612.46 crore on March 2025 . This represents a CAGR of -1.25% over 5 yearsThe Market Cap of Mercury Laboratories Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Medicamen Biotech Ltd for the Dec '25 is ₹ 47.44 crore as compare to the Sep '25 revenue of ₹ 47.54 crore. This represent the decline of -0.21% The revenue of Mercury Laboratories Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Medicamen Biotech Ltd for the Dec '25 is ₹ 4.91 crore as compare to the Sep '25 ebitda of ₹ 5.53 crore. This represent the decline of -11.21% The ebitda of Mercury Laboratories Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Medicamen Biotech Ltd changed from ₹ 0.8 crore to ₹ 1.63 crore over 7 quarters. This represents a CAGR of 50.19% The net profit of Mercury Laboratories Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Medicamen Biotech Ltd changed from 9.78 % on March 2021 to 13.45 % on March 2025 . This represents a CAGR of 6.58% over 5 yearsThe Dividend Payout of Mercury Laboratories Ltd changed from 7.87 % on March 2021 to 13.38 % on March 2025 . This represents a CAGR of 11.20% over 5 years .

About Medicamen Biotech Ltd

A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets.
The Company has presence over 35+ countries.
Its offerings include Finished Dosage Forms (FDF's) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market.
MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan).
The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.

About Mercury Laboratories Ltd

Mercury Laboratories Limited, the registered partnership firm started its business activity in year 1962.
Subsequently, it converted into Private Limited Company & incorporated in February, 1982.
Later, it converted into Limited Company in 1992 in Maharashtra.
The Company has obtained ISO 9001:2008 registrations.
It is engaged into the manufacturing and export of wide range of Pharmaceutical items.

FAQs for the comparison of Medicamen Biotech Ltd and Mercury Laboratories Ltd

Which company has a larger market capitalization, Medicamen Biotech Ltd or Mercury Laboratories Ltd?

Market cap of Medicamen Biotech Ltd is 362 Cr while Market cap of Mercury Laboratories Ltd is 91 Cr

What are the key factors driving the stock performance of Medicamen Biotech Ltd and Mercury Laboratories Ltd?

The stock performance of Medicamen Biotech Ltd and Mercury Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Medicamen Biotech Ltd and Mercury Laboratories Ltd?

As of May 18, 2026, the Medicamen Biotech Ltd stock price is INR ₹267.4. On the other hand, Mercury Laboratories Ltd stock price is INR ₹760.2.

How do dividend payouts of Medicamen Biotech Ltd and Mercury Laboratories Ltd compare?

To compare the dividend payouts of Medicamen Biotech Ltd and Mercury Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.